Results 131 to 140 of about 1,680,438 (318)

The neural crest‐associated gene ERRFI1 is involved in melanoma progression and resistance toward targeted therapy

Molecular Oncology, EarlyView.
ERRFI1, a neural crest (NC)‐associated gene, was upregulated in melanoma and negatively correlated with the expression of melanocytic differentiation markers and the susceptibility of melanoma cells toward BRAF inhibitors (BRAFi). Knocking down ERRFI1 significantly increased the sensitivity of melanoma cells to BRAFi.
Nina Wang, Qian Sun, Daniel Novak, Lei Zhu, Juliane Poelchen, Tamara Steinfass, Yiman Wang, Viktor Umansky, Jochen Utikal   +8 more
wiley   +1 more source

Plasma extrachromosomal circular DNA as a biomarker in EGFR‐targeted therapy of non‐small cell lung cancer

Molecular Oncology, EarlyView.
Detection of extrachromosomal circular DNA (eccDNA) in plasma samples from EGFR‐mutated non‐small cell lung cancer patients. Plasma was collected before and during treatment with the EGFR‐tyrosine kinase inhibitor osimertinib. Plasma eccDNA was detected in all cancer samples, and the presence of the EGFR gene on eccDNA serves as a potential biomarker ...
Simone Stensgaard, Sarmad Mehmood, Eva Boysen Fynboe Ebert, Peter Meldgaard, Anindya Dutta, Boe S. Sorensen   +5 more
wiley   +1 more source

Pre-treatment drug resistance among patients initiating antiretroviral therapy (ART) in Zimbabwe: 2008–2010 [PDF]

, 2016
More Mungati, Mutsa Mhangara, Elizabeth Gonese, Owen Mugurungi, Janet Dzangare, Stella Ngwende, Patience Musasa, Maureen Wellington, Gerald Shambira, T Apollo, Chunfu Yang, Joshua DeVos, Jennifer Sabatier, Peter H. Kilmarx, C. Chakanyuka-Musanhu, Mufuta Tshimanga   +15 more
openalex   +1 more source

Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker

Molecular Oncology, EarlyView.
Urinary LGALS3BP is elevated in bladder cancer patients compared to healthy controls as detected by the 1959 antibody–based ELISA. The antibody shows enhanced reactivity to the high‐mannose glycosylated variant secreted by cancer cells treated with kifunensine (KIF).
Asia Pece, Giulio Lovato, Ilaria Cela, Arianna Mercatelli, Benedetta Ferro, Jussi Nikkola, Sara Pagotto, Tommaso Grottola, Vincenzo De Laurenzi, Rossella Cicchetti, Antonio Marchetti, Luigi Schips, Rossano Lattanzio, Stefano Iacobelli, Emily Capone, Peter Black, Mads Daugaard, Michele Marchioni, Gianluca Sala   +18 more
wiley   +1 more source

Targeting the ubiquitin-proteasome system and drug therapy in colorectal cancer. [PDF]

J Mol Cell Biol
Su R, Shao Y, Wang Q, Liu D, Wang Y, Kong D, Qiu Y.   +6 more
europepmc   +1 more source

A cross-sectional survey of coronary plaque composition in individuals on non-statin lipid lowering drug therapies and undergoing coronary computed tomography angiography

, 2019
Subhi J. Al’Aref, Amanda Su, Heidi Gransar, Alexander R. van Rosendael, Asim Rizvi, Daniel S. Berman, Tracy Q. Callister, Augustin DeLago, Martin Hadamitzky, Jöerg Hausleiter, Mouaz H. Al‐Mallah, Matthew J. Budoff, Philipp A. Kaufmann, Gilbert Raff, Kavitha M. Chinnaiyan, Filippo Cademartiri, Erica Maffei, Todd C. Villines, Yong‐Jin Kim, Jonathon Leipsic, Gudrun Feuchtner, Gianluca Pontone, Daniele Andreini, Hugo Marques, Pedro de Araújo Gonçalves, Ronen Rubinshtein, Stephan Achenbach, Hyuk‐Jae Chang, Benjamin J.W. Chow, Ricardo C. Cury, Yao Lu, Jeroen J. Bax, Erica C. Jones, Jessica M. Peña, Leslee J. Shaw, James K. Min, Fay Y. Lin   +36 more
openalex   +2 more sources

Survivin and Aurora Kinase A control cell fate decisions during mitosis

Molecular Oncology, EarlyView.
Aurora A interacts with survivin during mitosis and regulates its centromeric role. Loss of Aurora A activity mislocalises survivin, the CPC and BubR1, leading to disruption of the spindle checkpoint and triggering premature mitotic exit, which we refer to as ‘mitotic slippage’.
Hana Abdelkabir, Shalitha Wickrama Arachchige, Sally P. Wheatley   +2 more
wiley   +1 more source

Emerging antiarrhythmic drug therapy for atrial fibrillation. [PDF]

Heart Rhythm O2
Lubitz SA, Taggart AKP, Gimpelewicz C, O'Donnell CJ.   +3 more
europepmc   +1 more source

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

Molecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia, Noelia Moares, Wenjie Yi‐He, Rosa Luna‐Espejo, Ricardo Fernandez‐Cisnal, Javier Ocaña‐Cuesta, Juan P. Muñoz‐Miranda, Antonio Gabucio, Cecilia M. Fernandez‐Ponce, Francisco Garcia‐Cozar   +9 more
wiley   +1 more source

Targeting Glutamine Transporters as a Novel Drug Therapy for Synovial Sarcoma. [PDF]

Cancers (Basel)
Thanh TD, Takada N, Yao H, Ban Y, Oebisu N, Hoshi M, Sang NTQ, Khanh NV, Quang DM, Thuy LTT, Dung TT, Terai H.   +11 more
europepmc   +1 more source